Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Javle, Milind (VerfasserIn) , Roychowdhury, Sameek (VerfasserIn) , Kelley, Robin Kate (VerfasserIn) , Sadeghi, Saeed (VerfasserIn) , Macarulla, Teresa (VerfasserIn) , Weiss, Karl Heinz (VerfasserIn) , Waldschmidt, Dirk Thomas (VerfasserIn) , Goyal, Lipika (VerfasserIn) , Borbath, Ivan (VerfasserIn) , El-Khoueiry, Anthony (VerfasserIn) , Borad, Mitesh J. (VerfasserIn) , Yong, Wei Peng (VerfasserIn) , Philip, Philip A. (VerfasserIn) , Bitzer, Michael (VerfasserIn) , Tanasanvimon, Surbpong (VerfasserIn) , Li, Ai (VerfasserIn) , Pande, Amit (VerfasserIn) , Soifer, Harris S. (VerfasserIn) , Shepherd, Stacie Peacock (VerfasserIn) , Moran, Susan (VerfasserIn) , Zhu, Andrew X. (VerfasserIn) , Bekaii-Saab, Tanios S. (VerfasserIn) , Abou-Alfa, Ghassan K. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 3 August 2021
In: The lancet. Gastroenterology & Hepatology
Year: 2021, Jahrgang: 6, Heft: 10, Pages: 803-815
ISSN:2468-1156
DOI:10.1016/S2468-1253(21)00196-5
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S2468-1253(21)00196-5
Verlag, lizenzpflichtig, Volltext: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00196-5/fulltext
Volltext
Verfasserangaben:Prof Milind Javle MD, Sameek Roychowdhury MD, Robin Kate Kelley MD, Saeed Sadeghi MD, Teresa Macarulla MD, Prof Karl Heinz Weiss MD, Dirk-Thomas Waldschmidt MD, Lipika Goyal MD, Prov Ivan Borbath MD, Anthony El-Khoueiry MD, Mitesh J. Borad MD, Wei Peng Yong MBChB, Philip A. Philip MD, Michael Bitzer MD, Surbpong Tanasanvimon MD, Ai Li PhD, Amit Pande MD, Harris S. Soifer PhD, Stacie Peacock Shepherd MD, Susan Moran MD, Prof Andrew X. Zhu MD, Tanios S. Bekaii-Saab MD, Prof Ghassan K. Abou-Alfa MD

MARC

LEADER 00000caa a2200000 c 4500
001 1787030849
003 DE-627
005 20220820113114.0
007 cr uuu---uuuuu
008 220124s2021 xx |||||o 00| ||eng c
024 7 |a 10.1016/S2468-1253(21)00196-5  |2 doi 
035 |a (DE-627)1787030849 
035 |a (DE-599)KXP1787030849 
035 |a (OCoLC)1341438875 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Javle, Milind  |e VerfasserIn  |0 (DE-588)1205686363  |0 (DE-627)1691312991  |4 aut 
245 1 0 |a Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements  |b mature results from a multicentre, open-label, single-arm, phase 2 study  |c Prof Milind Javle MD, Sameek Roychowdhury MD, Robin Kate Kelley MD, Saeed Sadeghi MD, Teresa Macarulla MD, Prof Karl Heinz Weiss MD, Dirk-Thomas Waldschmidt MD, Lipika Goyal MD, Prov Ivan Borbath MD, Anthony El-Khoueiry MD, Mitesh J. Borad MD, Wei Peng Yong MBChB, Philip A. Philip MD, Michael Bitzer MD, Surbpong Tanasanvimon MD, Ai Li PhD, Amit Pande MD, Harris S. Soifer PhD, Stacie Peacock Shepherd MD, Susan Moran MD, Prof Andrew X. Zhu MD, Tanios S. Bekaii-Saab MD, Prof Ghassan K. Abou-Alfa MD 
264 1 |c 3 August 2021 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 24.01.2022 
700 1 |a Roychowdhury, Sameek  |e VerfasserIn  |4 aut 
700 1 |a Kelley, Robin Kate  |e VerfasserIn  |4 aut 
700 1 |a Sadeghi, Saeed  |e VerfasserIn  |4 aut 
700 1 |a Macarulla, Teresa  |e VerfasserIn  |4 aut 
700 1 |a Weiss, Karl Heinz  |d 1976-  |e VerfasserIn  |0 (DE-588)130069531  |0 (DE-627)489615465  |0 (DE-576)297980203  |4 aut 
700 1 |a Waldschmidt, Dirk Thomas  |d 1964-  |e VerfasserIn  |0 (DE-588)132777339  |0 (DE-627)526930985  |0 (DE-576)271122781  |4 aut 
700 1 |a Goyal, Lipika  |e VerfasserIn  |4 aut 
700 1 |a Borbath, Ivan  |e VerfasserIn  |4 aut 
700 1 |a El-Khoueiry, Anthony  |e VerfasserIn  |4 aut 
700 1 |a Borad, Mitesh J.  |e VerfasserIn  |4 aut 
700 1 |a Yong, Wei Peng  |e VerfasserIn  |4 aut 
700 1 |a Philip, Philip A.  |e VerfasserIn  |4 aut 
700 1 |a Bitzer, Michael  |e VerfasserIn  |4 aut 
700 1 |a Tanasanvimon, Surbpong  |e VerfasserIn  |4 aut 
700 1 |a Li, Ai  |e VerfasserIn  |4 aut 
700 1 |a Pande, Amit  |e VerfasserIn  |4 aut 
700 1 |a Soifer, Harris S.  |e VerfasserIn  |4 aut 
700 1 |a Shepherd, Stacie Peacock  |e VerfasserIn  |4 aut 
700 1 |a Moran, Susan  |e VerfasserIn  |4 aut 
700 1 |a Zhu, Andrew X.  |e VerfasserIn  |4 aut 
700 1 |a Bekaii-Saab, Tanios S.  |e VerfasserIn  |4 aut 
700 1 |a Abou-Alfa, Ghassan K.  |e VerfasserIn  |0 (DE-588)137811330  |0 (DE-627)69608094X  |0 (DE-576)30532909X  |4 aut 
773 0 8 |i Enthalten in  |t The lancet. Gastroenterology & Hepatology  |d London : Elsevier, 2016  |g 6(2021), 10, Seite 803-815  |h Online-Ressource  |w (DE-627)872465713  |w (DE-600)2874542-5  |w (DE-576)479746354  |x 2468-1156  |7 nnas  |a Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements mature results from a multicentre, open-label, single-arm, phase 2 study 
773 1 8 |g volume:6  |g year:2021  |g number:10  |g pages:803-815  |g extent:13  |a Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements mature results from a multicentre, open-label, single-arm, phase 2 study 
856 4 0 |u https://doi.org/10.1016/S2468-1253(21)00196-5  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00196-5/fulltext  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220124 
993 |a Article 
994 |a 2021 
998 |g 130069531  |a Weiss, Karl Heinz  |m 130069531:Weiss, Karl Heinz  |d 50000  |e 50000PW130069531  |k 0/50000/  |p 6 
999 |a KXP-PPN1787030849  |e 4042361757 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"doi":["10.1016/S2468-1253(21)00196-5"],"eki":["1787030849"]},"title":[{"title_sort":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements","title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements","subtitle":"mature results from a multicentre, open-label, single-arm, phase 2 study"}],"person":[{"given":"Milind","role":"aut","display":"Javle, Milind","family":"Javle"},{"family":"Roychowdhury","display":"Roychowdhury, Sameek","given":"Sameek","role":"aut"},{"family":"Kelley","given":"Robin Kate","role":"aut","display":"Kelley, Robin Kate"},{"family":"Sadeghi","role":"aut","given":"Saeed","display":"Sadeghi, Saeed"},{"role":"aut","given":"Teresa","display":"Macarulla, Teresa","family":"Macarulla"},{"display":"Weiss, Karl Heinz","role":"aut","given":"Karl Heinz","family":"Weiss"},{"family":"Waldschmidt","display":"Waldschmidt, Dirk Thomas","role":"aut","given":"Dirk Thomas"},{"family":"Goyal","given":"Lipika","role":"aut","display":"Goyal, Lipika"},{"given":"Ivan","role":"aut","display":"Borbath, Ivan","family":"Borbath"},{"display":"El-Khoueiry, Anthony","given":"Anthony","role":"aut","family":"El-Khoueiry"},{"role":"aut","given":"Mitesh J.","display":"Borad, Mitesh J.","family":"Borad"},{"display":"Yong, Wei Peng","given":"Wei Peng","role":"aut","family":"Yong"},{"display":"Philip, Philip A.","given":"Philip A.","role":"aut","family":"Philip"},{"family":"Bitzer","display":"Bitzer, Michael","role":"aut","given":"Michael"},{"given":"Surbpong","role":"aut","display":"Tanasanvimon, Surbpong","family":"Tanasanvimon"},{"family":"Li","given":"Ai","role":"aut","display":"Li, Ai"},{"family":"Pande","display":"Pande, Amit","given":"Amit","role":"aut"},{"role":"aut","given":"Harris S.","display":"Soifer, Harris S.","family":"Soifer"},{"family":"Shepherd","given":"Stacie Peacock","role":"aut","display":"Shepherd, Stacie Peacock"},{"role":"aut","given":"Susan","display":"Moran, Susan","family":"Moran"},{"display":"Zhu, Andrew X.","role":"aut","given":"Andrew X.","family":"Zhu"},{"display":"Bekaii-Saab, Tanios S.","role":"aut","given":"Tanios S.","family":"Bekaii-Saab"},{"family":"Abou-Alfa","given":"Ghassan K.","role":"aut","display":"Abou-Alfa, Ghassan K."}],"recId":"1787030849","note":["Gesehen am 24.01.2022"],"relHost":[{"title":[{"partname":"Gastroenterology & Hepatology","title_sort":"lancet","title":"The lancet"}],"id":{"eki":["872465713"],"issn":["2468-1156"],"zdb":["2874542-5"]},"titleUni":[{"title":"The lancet (London)"}],"recId":"872465713","language":["eng"],"titleAlt":[{"title":"Gastroenterology and hepatology"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"London","publisher":"Elsevier","dateIssuedDisp":"[2016]-"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["Volume 1, issue 1 (September 2016)-"],"disp":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements mature results from a multicentre, open-label, single-arm, phase 2 studyThe lancet. Gastroenterology & Hepatology","part":{"pages":"803-815","extent":"13","text":"6(2021), 10, Seite 803-815","issue":"10","year":"2021","volume":"6"}}],"language":["eng"],"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"3 August 2021"}],"physDesc":[{"extent":"13 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Prof Milind Javle MD, Sameek Roychowdhury MD, Robin Kate Kelley MD, Saeed Sadeghi MD, Teresa Macarulla MD, Prof Karl Heinz Weiss MD, Dirk-Thomas Waldschmidt MD, Lipika Goyal MD, Prov Ivan Borbath MD, Anthony El-Khoueiry MD, Mitesh J. Borad MD, Wei Peng Yong MBChB, Philip A. Philip MD, Michael Bitzer MD, Surbpong Tanasanvimon MD, Ai Li PhD, Amit Pande MD, Harris S. Soifer PhD, Stacie Peacock Shepherd MD, Susan Moran MD, Prof Andrew X. Zhu MD, Tanios S. Bekaii-Saab MD, Prof Ghassan K. Abou-Alfa MD"]}} 
SRT |a JAVLEMILININFIGRATIN3202